Clinical reference Biomarker Directory
Back to directory

ADA

Established

ADA is a fluid-based enzyme test used mainly to diagnose tuberculous pleural effusion.

Also known as Adenosine aminohydrolase
In plain language

ADA is an enzyme measured in fluid drawn from around the lungs to help diagnose tuberculosis. A high level is a strong clue for TB, especially in regions where TB is common, but as TB becomes less common, doctors need higher cutoffs to avoid mistaking cancer-related fluid buildup for TB.

Biomarker & context

Adenosine deaminase (ADA) is an enzyme involved in purine metabolism that is released by activated T-lymphocytes. Elevated levels in body fluids reflect a cell-mediated immune response, most classically in tuberculous infection.

What it indicates

Pleural fluid ADA is a well-established, low-cost marker for diagnosing tuberculous pleural effusion (TPE), especially valuable in high-burden regions where invasive pleural biopsy carries real risk. It is also elevated in some malignant and other lymphocyte-rich effusions, requiring careful interpretation.

Diagnosis & clinical testing

Measured in pleural (or other body cavity) fluid; the traditional cutoff is ≥40 U/L, though optimal thresholds vary by population and TB prevalence — a 2026 Malaysian study proposed ≥36 U/L for better sensitivity in that setting, sometimes combined with an LDH/ADA ratio for improved specificity.

Guiding treatment

In low-to-medium TB prevalence settings (e.g., South Korea), the conventional 40 U/L cutoff performs poorly because malignant effusions increasingly populate the 40–70 U/L "gray zone," prompting recommendations for raised, locally-validated cutoffs (e.g., ≥70 U/L) to avoid false-positive TB diagnoses in cancer patients.

Clinical significance

A well-validated, inexpensive marker for TB pleuritis, with population-dependent optimal cutoffs.

References
  1. Shien, et al. (2026). Diagnostic utility of pleural fluid adenosine deaminase in tuberculous pleural effusion (ADATPE study). Journal of Thoracic Disease.
  2. Lee, J., et al. (2022). Investigating the appropriate ADA cutoff value for TPE diagnosis in a country with decreasing TB burden. Scientific Reports.